Company profile: 4D Path
1.1 - Company Overview
Company description
- Provider of H&E biopsy/resection image analysis, including 4D Q-Plasia OncoReader Breast (software-as-a-medical-device) for diagnostic accuracy in breast cancer and 4D Q-Plasia OncoReader Pan-Cancer, a cloud platform identifying cancer type, molecular subtypes, grades, and molecular profiles. Also offers automated detection and prognostic evaluation from H&E whole slide images and biomarker profiling and stratification for precision oncology.
Products and services
- 4D Q-Plasia OncoReader Pan-Cancer: Cloud-based platform that pinpoints cancer type, molecular subtypes, grades, and molecular profiles from H&E biopsy/resection images for pan-cancer characterization
- Automated H&E Image Analysis: Automated platform that detects cancers and delivers prognostic evaluation of cancers from H&E-stained whole slide images
- Biomarker Profiling and Stratification: H&E image-based service that delivers biomarker typing and prognostication to support precision oncology and stratification
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to 4D Path
Airna
HQ: United States
Website
- Description: Provider of RNA editing technologies and therapeutics, including the RESTORE+ RNA editing platform to optimize sequence, chemistry, and delivery for precise RNA editing to treat rare and common diseases. Offers RNA editing therapeutics for alpha-1 antitrypsin deficiency (AATD) and a pipeline addressing diseases with high unmet need.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Airna company profile →
10x Genomics
HQ: United States
Website
- Description: Provider of an innovative genomics platform delivering spatial and single-cell multiomic solutions: Visium HD Spatial Gene Expression for whole transcriptome analysis at single cell-scale with continuous tissue coverage; Chromium Single Cell Gene Expression with multiomic options; Chromium Single Cell Immune Profiling with gene expression, cell surface proteins, and full-length paired BCR/TCR; and Xenium In Situ for subcellular single-molecule RNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 10x Genomics company profile →
Citation Growth
HQ: Canada
Website
- Description: Provider of cannabis cultivation, processing, and branding services, producing high-quality cannabis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Citation Growth company profile →
Ethris
HQ: Germany
Website
- Description: Provider of mRNA therapeutics and LNP delivery solutions focused on respiratory diseases and vaccines. Offers the SNIM RNA platform for stabilized non-immunogenic mRNA therapies and the SNaP LNP platform for targeted, inhalable delivery. Pipeline includes ETH47, ETH42, and ETH45 for respiratory indications. Provides in-house and partnered manufacturing with HPLC-free processes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ethris company profile →
Genomic Vision
HQ: France
Website
- Description: Provider of novel genetic tests and research tools for life sciences, developed and commercialized using Molecular Combing, a proprietary single DNA molecule detection technology, combined with biomarker discovery; focused on DNA analysis and genetic testing in cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomic Vision company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for 4D Path
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to 4D Path
2.2 - Growth funds investing in similar companies to 4D Path
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for 4D Path
4.2 - Public trading comparable groups for 4D Path
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →